Pharmacokinetics of colistin in cerebrospinal fluid after intraventricular administration of colistin methanesulfonate

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 8, 2012, Pages 4416-4421

  Imberti, Roberto ^a   Cusato, Maria ^a   Accetta, Giovanni ^a   Marinò, Valeria ^b   Procaccio, Francesco ^c   Del Gaudio, Alfredo ^d   Iotti, Giorgio A ^a   Regazzi, Mario ^a  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b IRCCS NEUROMED   (Italy)

^c UNIVERSITY HOSPITAL OF VERONA   (Italy)

^d CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; CEFTAZIDIME; COLISTIMETHATE; COLISTIN; FOSFOMYCIN; LINEZOLID; MEROPENEM; RIFAMPICIN; SULTAMICILLIN; VANCOMYCIN;

ACINETOBACTER BAUMANNII; ADULT; AGED; ARTICLE; ASEPTIC MENINGITIS; CENTRAL NERVOUS SYSTEM INFECTION; CLINICAL ARTICLE; COMPARTMENT MODEL; COMPUTER PROGRAM; CORRELATION ANALYSIS; DRUG CEREBROSPINAL FLUID LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; KLEBSIELLA PNEUMONIAE; MALE; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SEIZURE; TREATMENT DURATION;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ADOLESCENT; ADULT; AGED; CENTRAL NERVOUS SYSTEM BACTERIAL INFECTIONS; COLISTIN; FEMALE; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; INJECTIONS, INTRAVENTRICULAR; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

EID: 84864390284     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00231-12     Document Type: Article

References (30)

1. Antachopoulos C, et al. 2010. Serum and cerebrospinal fluid levels of colistin in pediatric patients. Antimicrob. Agents Chemother. 54:3985-3987.
2. Barnett M, Bushby SRM, Wilkinson S. 1964. Sodium sulphomethyl derivatives of polymyxins. Br. J. Pharmacol. 23:552-574.
3. Bergen PJ, et al. 2008. Comparison of once-, twice- and thrice-daily dosing of colistin on antibacterial effect and emergence of resistance: studies with Pseudomonas aeruginosa in an in vitro pharmacodynamic model. J. Antimicrob. Chemother. 61:636-642. (Pubitemid 351321139)
4. Bergen PJ, Li J, Rayner CR, Nation RL. 2006. Colistin methanesulphonate is an inactive prodrug of colistin against Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 50:1953-1958. (Pubitemid 43807511)
5. Cook AM, Mieure KD, Owen RD, Pesaturo AB, Hatton J. 2009. Intracerebroventricular administration of drugs. Pharmacotherapy 29:832-845.
6. Dost FH. 1968. Grundlagen der pharmacokinetic, p 169. Georg Thieme Verlag, Stuttgart, Germany.
7. Dudhani RV, et al. 2010. Elucidation of pharmacokinetic/pharmacodynamic determinant of colistin activity against Pseudomonas aeruginosa in murine thigh and lung infection model. Antimicrob. Agents Chemother. 54:1117-1124.
8. Dudhani RV, Turnidge JD, Nation RL, Li J. 2010. fAUC/MIC is the most predictive pharmacokinetic/pharmacodynamic index of colistin against Acinetobacter baumannii in murine thigh and lung infection models. J. Antimicrob. Chemother. 65:1984-1990.
9. Falagas ME, Bliziotis IA, Tam VH. 2007. Intraventricular or intrathecal use of polymyxins in patients with Gram-negative meningitis: a systematic review of the available evidence. Int. J. Antimicrob. Agents 29:9-25. (Pubitemid 44959774)
10. Imberti R, et al. 2010. Steady-state pharmacokinetics and BAL concentration of colistin in critically ill patients after IV colistin methanesulfonate administration. Chest 138:1333-1339.
11. Jiménez-Mejías ME, et al. 2002. Cerebrospinal fluid penetration and pharmacokinetic/pharmacodynamic parameters of intravenously administered colistin in a case of multidrug-resistant Acinetobacter baumannii meningitis. Eur. J. Clin. Microbiol. Infect. Dis. 21:212-214.
12. Jin L, Li J, Nation RL, Nicolazzo JA. 2011. Impact of p-glycoprotein inhibition and lipopolysaccharide administration on blood-brain barrier transport of colistin in mice. Antimicrob. Agents Chemother. 55:502-507.
13. Khawcharoenporn T, Apisarnthanarak A, Mundy LM. 2010. Intrathecal colistin for drug-resistant Acinetobacter baumannii central nervous system infection: a case series and systematic review. Clin. Microbiol. Infect. 16:888-894.
14. Kim K, Kang HS, Sohn CH, Oh BM. 2011. Cauda equina syndrome misdiagnosed as aggravated hydrocephalus: neurological complication of intrathecal colistin in post-surgical meningitis. Acta Neurochir. (Wien) 153:425-427.
15. Koch-Weser J, et al. 1970. Adverse effects of sodium colistimethate. Manifestations and specific reaction rates during 317 courses of therapy. Ann. Intern. Med. 72:857-868.
16. Le Gall JR, et al. 1995. Customized probability models for early severe sepsis in adult intensive care patients. Intensive Care Unit Scoring Group. JAMA 273:644-650.
17. Li J, et al. 2003. Steady-state pharmacokinetics of intravenous colistin methanesulphonate in patients with cystic fibrosis. J. Antimicrob. Chemother. 52:987-992. (Pubitemid 38008420)
18. Li J, et al. 2001. A simple method for the assay of colistin in human plasma, using pre-column derivatization with 9-fluorenylmethyl chloroformate in solid-phase extraction cartridges and reversed-phase high-performance liquid chromatography. J. Chromatogr. B Biomed. Sci. Appl. 761:167-175. (Pubitemid 32817106)
19. Li J, et al. 2006. Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect. Dis. 6:589-601.
20. Li J, Turnidge J, Milne R, Nation RL, Coulthard K. 2001. In vitro pharmacodynamic properties of colistin and colistin methanesulphonate against Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Antimicrob. Agents Chemother. 45:781-785. (Pubitemid 32182025)
21. Markantonis SL, et al. 2009. Penetration of colistin into cerebrospinal fluid. Antimicrob. Agents Chemother. 53:4907-4910.
22. Markou N, et al. 2008. Colistin serum concentrations after intravenous administration in critically ill patients with serious multidrug-resistant, gram-negative bacilli infections: a prospective, open-label, uncontrolled study. Clin. Ther. 30:143-151. (Pubitemid 351834728)
23. Nau R, Sörgel F, Eiffert H. 2010. Penetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections. Clin. Microbiol. Rev. 23:858-883.
24. Ng J, Gosbell IB, Kelly JA, Boyle MJ, Ferguson JK. 2006. Cure of multiresistant Acinetobacter baumannii central nervous system infections with intraventricular or intrathecal colistin: case series and literature review. J. Antimicrob. Chemother. 58:1078-1081.
25. Plachouras D, et al. 2009. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria. Antimicrob. Agents Chemother. 53:3430-3436.
26. Ritschel WA, Kearns GL (ed). 2004. Pharmacokinetics of multiple dosing, p 200-219. In Handbook of basic pharmacokinetics, 6th ed. American Pharmacists Association, Washington, DC.
27. Tunkel AR, et al. 2004. Practice guidelines for the management of bacterial meningitis. Clin. Infect. Dis. 39:1267-1284.
28. van de Beek D, Drake JM, Tunkel AR. 2010. Nosocomial bacterial meningitis. N. Engl. J. Med. 362:146-154.
29. Vincent JL, et al. 1996. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med. 22:707-710.
30. Wynne JM, Cooke EM. 1996. Passage of chloramphenicol and sodium colistimethate into the cerebrospinal fluid. Studies of hydrocephalic children. Am. J. Dis. Child. 112:422-426.